Introduction: Genomic profiling informs selection of matched targeted therapies as part of routine clinical care in NSCLC. Tissue biopsy is the criterion standard; however, genomic profiling of blood-derived circulating tumor DNA (ctDNA) has emerged as a minimally invasive alternative.
Introduction
The treatment of advanced NSCLC with matched targeted therapies is part of routine clinical practice and has become a paradigm of personalized oncology. The National Comprehensive Cancer Network (NCCN) guidelines for NSCLC now recommend broad molecular profiling, including testing for alterations in 7 genes (EGFR, ALK receptor tyrosine kinase gene [ALK] , ROS1, BRAF, MNNG HOS Transforming gene [MET] , erb-b2 receptor tyrosine kinase 2 gene [ERBB2], and ret protooncogene gene [RET] ) to inform selection of effective targeted therapies, many of which are now approved for the treatment of advanced NSCLC, as well as testing for KRAS mutations. 1 Furthermore, diverse alterations predicting sensitivity and resistance to targeted therapies continue to be elucidated, [2] [3] [4] making comprehensive assessment throughout the course of disease progression critical for optimal patient care.
Tissue-based genomic testing of cancer specimens is currently the criterion standard, but sequencing of circulating tumor DNA (ctDNA) isolated from minimally invasive liquid biopsy specimens is now also routinely used in clinical care in NSCLC. As more patients receive multiple lines of targeted therapy, the demand for repeat biopsy upon progression has become greater. Nonetheless, limitations in performing serial tissue biopsies presents frequent challenges. Insufficient tissue is a limiting factor for comprehensive genomic analysis in more than 25% of NSCLC cases 5 ; blood-based ctDNA assays, as well as improvements in tissue requirements for traditional assays, can provide an alternative for these patients. Additionally, assays utilizing ctDNA sequencing may confer the advantage of detecting heterogeneous alterations in metastatic lesions. 6 Although test agreement has been described for mutations in genes such as EGFR, the concordance between tumor and ctDNA for diverse genomic alterations (GAs) has not been reported in large population-based cohorts in NSCLC. Moreover, whether the GA frequencies that are seen in ctDNA are similar to those reported in large tissue-based next generation sequencing (NGS) studies remains unclear.
We conducted a retrospective study of ctDNA-based genomic profiling performed during routine clinical care by using a 62-gene panel from 1552 patients with advanced NSCLC. We compared alterations detected in ctDNA with both those detected in temporally matched individual patient tissue samples and available tissue databases.
Methods
Genomic profiling of ctDNA was performed on blood samples from 1552 consecutive patients with advanced NSCLC that were submitted by clinicians as part of routine clinical care between May 2016 and May 2017. Testing was performed in a Clinical Laboratory Improvement Amendments-certified/College of American Pathologist-accredited laboratory (Foundation Medicine, Inc., Cambridge, MA). Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (protocol No. 20152817).
The assay methodology has been described in detail previously. 7 Briefly, 20 mL of peripheral whole blood was collected for genomic profiling of ctDNA. Plasma was isolated, and 20 to 100 ng of cell-free DNA (cfDNA) was extracted to create adapted sequencing libraries before hybrid capture and sample-multiplexed sequencing (Illumina HiSeq 2500 or 4000 sequencer, Illumina, San Diego, CA) to a median unique exon coverage depth of 6873Â for 62 genes (Supplementary Tables 1 and 2 ). cfDNA quality was confirmed by smear analysis by using a TapeStation system (Agilent Technologies, Santa Clara, CA) to confirm that the size of the quantitated DNA fragments was consistent with cfDNA. Results were analyzed for alterations at low allele frequencies (AFs), including substitutions (AF !0.1%), short insertions/deletions or indels (AF !0.1%), and rearrangements, as well as copy number amplification. Maximum somatic AF (MSAF) measures the AF of all somatic alterations (including reportable GAs, variants of unknown significance, and synonymous mutations) identified per sample; alterations in the Exome Aggregation Consortium database are removed from the alteration list for MSAF calculation (as they are likely germline alterations) and Single Nucleotide Polymorphism database variants are also excluded. The maximum AF identified out of all alterations measured is defined as the MSAF, which can provide an estimate of the ctDNA fraction in blood. Variants of unknown significance were included for MSAF calculations but excluded from remaining analyses throughout the manuscript.
A total of 41 patients in this series had a paired tissue sample that was sequenced according to previously published methods 8, 9 ; of these 41 patients, 33 had ctDNA samples with evidence of ctDNA present in the blood sample. All tissue and ctDNA samples included in the comparison analysis (n ¼ 33) passed quality metrics for amount of input cfDNA (>20 ng) and sequence coverage (>5000Â). For comparative analyses with prior studies, data from the FoundationCORE database (tissue samples analyzed using the FoundationOne assay, Foundation Medicine) and The Tumor Cancer Genome Atlas (TCGA) 10 were extracted from the cBio portal. 11 Ordinal relationships were examined by using the Mann-Whitney U test; categorical relationships were examined by using Pearson's chi-square test with the Yates continuity correction when applicable.
Results

Patient Characteristics
Hybrid capture-based genomic profiling was performed on ctDNA samples collected from 1552 unique patients with advanced NSCLC. Most patients had lung adenocarcinoma (68%), followed by NSCLC not otherwise specified (24%), lung squamous cell carcinoma (6%), lung large cell carcinoma (1%), and lung sarcomatoid carcinoma (0.4%) (Supplementary Fig. 1A ). The median patient age was 69 years (range 8-95), and 54% of patients were women ( Table 1) .
Distribution of GAs Identified in ctDNA
The MSAF was calculated for each case and used to determine whether there was evidence of ctDNA in the blood sample; the MSAF was greater than zero in 80% of cases (1243 of 1552). Among this subset, the median MSAF was 1.44% and at least one reportable GA was detected in 86% of cases (1075 of 1243). The fraction of cases with detectable ctDNA was relatively consistent among disease subtypes, although it was lowest in adenocarcinomas (Table 1 and Supplementary Fig. 1B) Among 1243 cases with evidence of ctDNA, the most frequently altered genes were tumor protein p53 gene (TP53) (59%), EGFR (25%), KRAS (17%), neurofibromin 1 gene (NF1) (7.1%), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) (4.3%) (Fig. 1A) . BRCA1, DNA repair associated gene (BRCA1)/ BRCA2, DNA repair associated gene 2 (BRCA2) short variants (SVs) or truncating rearrangements were observed in 3.3% of cases. An NSCLC NCCN guideline GA was found in 32% of cases (398 of 1243). These included EGFR SVs (22%), ALK rearrangements (2.7%), MET amplification or exon 14 splice site mutations (2.2%), ERBB2 SVs (1.1%), RET rearrangements (1.0%), BRAF V600E (0.6%), and ROS1 rearrangements (0.5%) (Fig. 1B) . KRAS SVs were identified in 16% of all cases and were largely mutually exclusive from cases with other relevant GAs, with just six cases having an NCCN NSCLC GA and a KRAS mutation. Kinase fusions were observed in 5% of cases (59 of 1243) and involved genes encoding six unique kinases (ALK, RET, ROS1, fibroblast growth factor receptor 3 gene [FGFR3], platelet derived growth factor receptor alpha gene [PDGFRA] , and platelet derived growth factor receptor beta gene [PDGFRB] ) and 15 unique fusion partners, including most commonly echinoderm microtubule associated protein like 4 gene (EML4)-ALK (n ¼ 32), kinesin family member 5B 
Comparison of ctDNA with Paired Tissue and Tissue Databases
We compared common GAs in this ctDNA data set with those in our large clinical tissue NSCLC database (71% adenocarcinoma) and with those reported in the lung adenocarcinoma TCGA. 10 The frequencies of common SVs in this ctDNA study were largely similar to those observed among 21,500 tissue samples included in the FoundationCORE database for patients with NSCLC ( Fig. 2A) . These included TP53 (58.3% versus 62.0%), NF1 (6.84% versus 5.87%), and PIK3CA (4.02% versus 6.01%). However, EGFR and KRAS were notable exceptions, with EGFR SVs being significantly more common in ctDNA (23.8% versus 14.8%) and KRAS SVs being significantly more common in tissue (16.3% versus 29.0%) (p < 0.0001 in both cases), likely reflecting the difference in the patient populations studied. Gene amplification was less frequently detected in ctDNA samples from this study than in NSCLC samples in the FoundationCORE and TCGA databases (Fig. 2B) . EGFR, MET, ERBB2, and FGFR1 were amplified in 3.4%, 1.3%, 1.1%, and 1.0% of ctDNA samples, respectively, and in 5.4%, 2.9%, 2.4%, and 2. Figure 3 . Concordance between genomic alterations (GAs) found in circulating tumor DNA (ctDNA) and matched tissue from 33 patients with NSCLC. (A) Days between ctDNA and tissue collection (<30 for all cases) and maximum somatic allele frequency (MSAF) (>0 for all cases) are shown. Concordant/shared GAs are in blue, GAs found only in tissue are in red, and GAs found only in ctDNA are in pink. All alterations covered by both the tissue and ctDNA assay are shown. For samples with multiple unique mutations in a given gene, the number of mutations is indicated. (B) Box-and-whisker plot showing mutant allele frequency of short variant alteration detected in match ctDNA samples: box spans first and third quartiles, the median is denoted by the horizontal line in the box, whiskers indicate maximum and minimum values within 1.5 times the inner quartile range. ERBB2, erb-b2 receptor tyrosine kinase 2 gene; FGFR2, fibroblast growth factor receptor 2 gene; ARAF, A-Raf proto-oncogene, serine threonine kinase gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; PTEN, phosphatase and tensin homolog gene; NF1, neurofibromin 1 gene; GNAS, GNAS complex locus gene; TP53, TP53, tumor protein p53 gene; BRCA2, BRCA2, DNA repair associated gene; CTNNB1, catenin beta 1 gene; CDH1, cadherin 1 gene; CDKN2A, cyclin dependent kinase inhibitor 2A gene; JAK2, Janus kinase 2 gene; KIT, KIT proto-oncogene receptor Comparison of GAs detected in ctDNA with those detected in temporally matched tissue samples collected within 30 days and analyzed by using similar hybrid capture-based genomic profiling assays was available for 41 patients (Supplementary Table 5 ). Only alterations covered by both assays were assessed. A total of 119 alterations were detected in the 41 matched tissue samples, of which 66 (55%) were also detected in matched blood samples. For eight patients, however, no evidence of ctDNA was detected in the matched blood sample. Therefore, for the remaining analysis we excluded matched samples without evidence of ctDNA in the blood; however, blood samples with evidence of ctDNA but without reportable variants detected were included, leaving 33 remaining paired samples. A total of 103 alterations were detected in the 33 matched tissue samples, of which 66 (64%) were also detected in matched ctDNA. This included 78% of SVs (58 of 74), 16% of amplifications (four of 25) , and four of four rearrangements (Fig. 3A) . Conversely, 81% of alterations (66 of 81) detected in ctDNA were also detected in matched tissue. With limitation specifically to targetable alterations in the NSCLC NCCN guidelines (27 alterations in 21 matched cases), 85% (23 of 27) of alterations detected in tissue were also detected in ctDNA, and no alterations were detected in ctDNA only. A total of 20 EGFR alterations were detected in 14 matched tissue cases, and of these, 80% (16 of 20) were also detected in ctDNA. In two cases with low MSAFs (0.2% and 0.5%) both the exon 19 deletion and T790M were detected only in tissue (Fig. 3A [patients 15 and 18] ). The distribution of mutant AFs for SVs detected in matched ctDNA samples is shown (Fig. 3B ).
Discussion
In this study, we have reported results of hybrid capture-based NGS of 1552 NSCLC samples submitted for testing during the course of clinical care. Evidence of ctDNA in the blood was detected in 80% of samples, which is similar to the rate in advanced NSCLC or lung adenocarcinoma in other recent reports. 12, 13 Undetectable ctDNA may indicate low tumor burden or a nonshedding tumor, which has been putatively associated with more favorable prognosis. 14 We observed that samples without evidence of ctDNA were more likely to come from younger patients with adenocarcinoma, although this may be due to the fact that patients in this subset were more likely to have been actively treated with matched targeted therapy at the time of blood draw rather than to the inherent biology of the disease.
In cases with evidence of ctDNA present, at least one reportable alteration was detected in 86% of cases, and frequently altered genes included TP53 (59%), EGFR (25%), KRAS (17%), NF1 (7.1%), and PIK3CA (4.3%), which is similar overall to the results reported in a smaller study of 88 patients with lung adenocarcinoma. 12 Another study reported EGFR mutations (including T790M) in a larger fraction of ctDNA samples, but the patient population studied was likely enriched for patients who received targeted therapy. 13 An NSCLC NCCN guideline GA was detected in 32% of cases in our study and they were largely mutually exclusive with KRAS SVs. The rate of 1.5% of NCCN driver-positive cases with KRAS mutations (6 of 398) was similar to that seen in our FoundationCORE tissue database (data not shown), although it is possible that these cooccurring KRAS mutations found in ctDNA samples represent tumor heterogeneity or clonal hematopoiesis of indeterminate potential (CHIP). 15 More than one NSCLC NCCN GA was observed in 17 cases, a subset of which represent cases with acquired resistance to EGFRtargeted therapy. 16 Rare but putatively actionable kinase rearrangements were detected in 5.1% of cases, including ALK, RET, ROS1, FGFR3-transforming acidic coiled-coil containing protein 3 gene (TACC3), and PDGFRA/B fusions, as well as ALK intron 19 rearrangements and EGFR KDDs. The current FoundationACT ctDNA assay includes intron baiting for fusion detection of six genes, including ALK, RET, ROS1, FGFR3, EGFR, and PDGFRA; however, rearrangements with noncanonical breakpoints in other introns or involving genes without intron baiting may be underrepresented here.
The frequencies of SVs in ctDNA versus tissue were generally similar across commonly mutated genes. Notably, EGFR SV, including the T790M resistance mutation (7% versus 2% [p < 0.0001]), were significantly more common in ctDNA than in tissue, which is likely indicative of ctDNA testing being more readily adopted in the setting of progression during targeted therapies; thus, common targetable alterations and resistance mechanisms would be enriched in this population. We also observed three NSCLC ctDNA cases with IGH rearrangements, and an additional 36 cases (3%) with Janus kinase 2 gene (JAK2) V617F mutations. These alterations are rare in NSCLC but common in hematologic malignancies, suggesting that GAs found in ctDNA are not tyrosine kinase gene; CDK4, cyclin-dependent kinase 4 gene; CDK6, cyclin-dependent kinase 6 gene; CCND1, cyclin D1 gene; MDM2, MDM2 proto-oncogene gene; MYC, v-myc avian myelocytomatosis viral oncogene homolog gene; MYCN, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog gene; PD-L1, programmed death ligand 1 gene (also known as CD274 molecule); EML4, echinoderm microtubule associated protein like 4 gene; ALK, ALK receptor tyrosine kinase gene; RE, rearrangement.
always derived from the expected tumor. [17] [18] [19] The MSAF in these cases was not notably different from the overall population (median 1.66%), and in some cases known driver alterations in NSCLC were also present. Clinical implications of these incidental findings in ctDNA of patients with NSCLC, including the potential for diagnosis of a secondary malignancy or CHIP, 20 warrant further study.
One limitation of this study is the lack of available information regarding clinical characteristics and treatment course for most patients. However, multiple published reports have described patients with both known and novel mechanisms of acquired resistance detected by using this ctDNA assay and included in the current study cohort (Supplementary Table 6 ). Novel and newly emerging EGFR resistance mutations, including G724S, and multiple solvent front mutations (G769S/R, L792F/ H, and C797S/R) occurring in cis with T790M, were detected in blood-based ctDNA samples collected after progression in patients taking osimertinb. [21] [22] [23] In some cases, multiple tertiary EGFR resistance alterations were detected in trans in the same blood sample, suggesting that these mutations were subclonal.
22 FGFR3-TACC3 fusions were also identified as acquired bypass resistance mechanisms to all generations of EGFR tyrosine kinase inhibitors. 4, 24 In MET-driven NSCLC, MET Y1230C was detected in the ctDNA of a patient with a known MET exon 14 skipping mutation following treatment with crizotinib, and another report showed EGFR amplification as a likely resistance mechanism to crizotinib in a case of MET-amplified NSCLC. 25, 26 These clinical cases highlight the utility of ctDNA testing, particularly to detect diverse mechanisms of acquired resistance and avoid rebiopsy after progression during targeted therapy.
In comparing temporally matched tissue and ctDNA samples from 33 patients with evidence of ctDNA in the blood, we observed relatively high concordance for SV alterations. Of the SVs detected in tissue, 78% were also detected in paired ctDNA, whereas 81% of alterations in ctDNA were also detected in tissue. EGFR SVs were concordant in 12 of 14 cases; in both cases with missed alterations, the ctDNA fraction was low (MSAF 0.5%), suggesting that the patient may have had a low disease burden and/or may have been undergoing EGFR targeted therapy when the blood sample was collected. This may be indicative of one challenge of using ctDNA for genomic profiling in NSCLC, as sufficient levels of ctDNA are necessary to detect genomic drivers, and more sensitive detection may be possible if tissue biopsy is feasible. Most of the 15 SVs detected in ctDNA but not in matched tissue were TP53 or NF1 SVs, both of which were identified as common subclonal driver alterations in a recent study of NSCLC evolution. 27 The clinical implications of these nontruncal mutations detected only in ctDNA require further study, and these alterations could also be indicative of CHIP rather than somatic mutations from the lung cancer itself. Although the number of matched samples available for evaluation was small, we observed 100% concordance for detection of fusions in paired ctDNA and tissue samples, which is consistent with recent analysis of ALK-driven NSCLC. 28 In an additional eight paired cases no evidence of ctDNA was detected in the blood sample (MSAF ¼ 0) and these samples were excluded from concordance analysis presented in Figure 3A (n ¼ 33), as were samples with insufficient tissue fraction (<20%). In the paired tissue samples for these 8 cases, a total of 16 reportable alterations were detected, highlighting the utility of tissue testing in cases in which the level of ctDNA is insufficient.
In contrast, only 16% of gene amplifications detected in tissue were also detected in paired samples with evidence of ctDNA. Rates of detected amplification were also significantly lower across our ctDNA data set than across the FoundationCORE and TCGA data sets. In contrast, a recent study in lung adenocarcinoma reported notably higher rates of EGFR (8.0%), MET (6.8%), and BRAF (4.5%) amplification than we have reported herein (3.4%, 1.3%, 0%, respectively), which may be due to a number of factors, including the criteria for reporting amplifications, variation in the patient populations tested, or levels of ctDNA present in the blood samples. 12 MET amplification has been identified as both a targetable primary driver and as an acquired resistance mechanism in 5% to 10% of EGFR-mutated NSCLCs; amplification of genes encoding other targetable kinases, including EGFR, ERBB2, and FGFR1, have also been implicated as drivers or acquired resistance mechanisms in NSCLC. 25, [29] [30] [31] [32] Less robust detection of amplifications in samples with lower ctDNA fractions has been observed previously in multiple solid tumor studies with use of various assays, suggesting that this may be a limitation generally for ctDNA testing. [33] [34] [35] Herein, we found that the ctDNA fraction was significantly higher in samples in which a gene amplification event was detected than in samples with no amplification detected ( Supplementary Fig. 2A ). Further, among paired samples with gene amplification detected, the copy number in cases with amplification in both blood and tissue was significantly higher than in cases in which amplification was detected only in tissue ( Supplementary Fig. 2B, C) . We acknowledge that this analysis is limited by the relatively small number of paired samples with amplification events available for analysis.
The use of NGS-based genomic profiling of bloodbased ctDNA samples for advanced NSCLC is promising, particularly as additional lines of targeted therapy continue to become available. Currently, there are only , which are limited to detection of common EGFR mutations. Blood-based ctDNA testing potentially allows for repeat assessment of a patient's cancer at each stage of progression, avoiding the need for invasive and sometimes prohibitive tissue biopsy while allowing for detection of heterogeneous and dynamic events that may occur in the setting of acquired resistance. [36] [37] [38] Potentially important applications for ctDNA assays that are beyond the scope of this study include monitoring of tumor burden, minimal residual disease, recurrence, and prognosis. [39] [40] [41] Nonetheless, the current commercially available ctDNA assays are typically composed of limited gene panels and do not allow for detection of genomic signatures predicting efficacy of immunotherapies, such as microsatellite instability, tumor mutational burden, and programmed death ligand 1 immunohistochemistry. However, we anticipate that future versions of commercially available ctDNA assays will be more comprehensive, and prospective clinical trials in NSCLC are ongoing. 42, 43 Overall, ctDNA testing in NSCLC may provide a valuable alternative or complement to tissue testing, particularly in cases in which tissue biopsy is prohibitive or repeat genomic assessment in the setting of disease progression is indicated.
